A phase Il trial to assess the impact of β2 adrenergic receptor (β2-AR) blockade in metastatic triple negative breast cancer (mTNBC).

Authors: Shipra Gandhi, Lindsay Moshides, Hans Minderman, Hemn Mohammadpour, Spencer Rosario, Kevin Kalinsky, Elizabeth A. Repasky

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1140

Source: Full article

---

Abstract

TPS1140